Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Simcere Pharmaceutical GroupFRA:S2P -2.86%86 OCF Yield % is 6.77 as of Jul. 25, 2026, which is 464% above its 10-year median of 1.20. GuruFocus rates FRA:S2P with a GF Score™ of 86/100 and a GF Value™ of €1.15 (Modestly Overvalued). Among 1,006 Drug Manufacturers companies, Simcere Pharmaceutical Group ranks better than 67.3% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Simcere Pharmaceutical Group OCF Yield % Explanation
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Simcere Pharmaceutical Group OCF Yield % Related Terms
Simcere Pharmaceutical Group OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Simcere Pharmaceutical Group's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Simcere Pharmaceutical Group OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Simcere Pharmaceutical Group's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Simcere Pharmaceutical Group's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Simcere Pharmaceutical Group (FRA:S2P) has a OCF Yield % of 6.77 as of Jul. 25, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Simcere Pharmaceutical Group and its competitors. This is 464% above median its historical median of 1.20. According to the industry distribution chart, Simcere Pharmaceutical Group ranks #329 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 32.7%.
Is Simcere Pharmaceutical Group's OCF Yield % too high?
Simcere Pharmaceutical Group's current OCF Yield % of 6.77 is 464% above median its 10-year median of 1.20. The Drug Manufacturers industry median OCF Yield % is 3.66. Simcere Pharmaceutical Group's value of 6.77 is 85% above this industry median. Based on the distribution chart, Simcere Pharmaceutical Group ranks #329 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Simcere Pharmaceutical Group has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Simcere Pharmaceutical Group's OCF Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Simcere Pharmaceutical Group ranks #329 out of 1006 companies for OCF Yield %. This puts Simcere Pharmaceutical Group in the upper half of its industry. The industry median OCF Yield % is 3.66. Simcere Pharmaceutical Group's value of 6.77 is 85% above this benchmark. While the company's 10-year median is 1.20 vs. the industry median of 3.66, Simcere Pharmaceutical Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.66, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Simcere Pharmaceutical Group's current OCF Yield % of 6.77 is 85% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Simcere Pharmaceutical Group and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simcere Pharmaceutical Group's current OCF Yield % is 6.77, which is 464% above median its own 10-year median of 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simcere Pharmaceutical Group stock overvalued right now?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group (FRA:S2P) is currently considered Modestly Overvalued. The stock's GF Value™ is €1.15, compared to a current price of €1.36 — trading 18.3% above its estimated fair value. The current OCF Yield % is 6.77, which is 464% above median its 10-year median of 1.20 and 85% above the Drug Manufacturers industry median of 3.66. Simcere Pharmaceutical Group's overall GF Score™ is 86/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Simcere Pharmaceutical Group (FRA:S2P), the current OCF Yield % is 6.77 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Simcere Pharmaceutical Group (FRA:S2P) Overvalued in 2026?
Based on GuruFocus' analysis, Simcere Pharmaceutical Group stock appears to be overvalued.
The current stock price of €1.36 is trading 18.3% above its estimated GF Value™ of €1.15.
GuruFocus considers Simcere Pharmaceutical Group to be Modestly Overvalued.
Key valuation signals for FRA:S2P:
OCF Yield %: 6.77 (464% above median its 10-year median of 1.20)
GF Value™: €1.15 vs. price of €1.36 (18.3% above fair value)
Industry Position: 85% above the Drug Manufacturers median (#329 of 1006)
No single metric tells the full story. See the FRA:S2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. The company has a diversified product portfolio focused on therapeutic areas, including, neuroscience, anti-oncology, autoimmune, and antiinfection. The company's products include Endostar, Enweida, Enzeshu, Iremod, Quviviq, Cosela, Sanbexin and Others.
86GF Score
Get the complete analysis for FRA:S2P
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S2P has been successfully added to your 
